Published in Oncotarget on September 27, 2016
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
The epigenomics of cancer. Cell (2007) 30.91
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32
DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet (2008) 15.45
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
High density DNA methylation array with single CpG site resolution. Genomics (2011) 10.35
DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics (2012) 9.31
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One (2012) 5.03
Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics (2013) 4.61
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2007) 4.01
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 2.38
Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst (2006) 2.37
Breast cancer mortality trends in England and the assessment of the effectiveness of mammography screening: population-based study. J R Soc Med (2013) 2.20
Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res (2010) 2.10
DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol (2011) 1.92
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer (2002) 1.82
Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers. Cancer Epidemiol Biomarkers Prev (2012) 1.76
BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat (2010) 1.76
Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst (2000) 1.64
Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res (Phila) (2012) 1.61
Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer (2012) 1.61
Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One (2011) 1.55
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
Spongiform degeneration in mahoganoid mutant mice. Science (2003) 1.51
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.40
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet (2009) 1.33
New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat (2006) 1.25
DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis (2012) 1.22
DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J (2012) 1.21
DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol (2012) 1.19
F2RL3 methylation in blood DNA is a strong predictor of mortality. Int J Epidemiol (2014) 1.06
BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol (2012) 0.97
Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat (2014) 0.92
Impaired receptor clustering in congenital myasthenic syndrome with novel RAPSN mutations. Neurology (2006) 0.91
Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prev Res (Phila) (2013) 0.88
Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics (2015) 0.88
DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood. Int J Cancer (2014) 0.84
Failure of lysosome clustering and positioning in the juxtanuclear region in cells deficient in rapsyn. J Cell Sci (2015) 0.79
Screening mammography--early detection or over-diagnosis? Contribution from Australian data. Climacteric (2014) 0.78
Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol (2015) 0.89
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum Mol Genet (2015) 0.85
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Sci Rep (2015) 0.80
Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. Oncotarget (2017) 0.75
Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. Oncotarget (2017) 0.75